| Previous close | 115.80 |
| Open | 113.80 |
| Bid | 112.90 x 0 |
| Ask | 113.40 x 0 |
| Day's range | 113.80 - 113.80 |
| 52-week range | 100.30 - 130.00 |
| Volume | |
| Avg. volume | 0 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 25 Jul 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireIpsen expands collaboration and license agreement for development of Cabometyx® in advanced neuroendocrine tumors based on positive CABINET Phase III trial
Decision adds to existing collaboration agreement with Exelixis, permitting Ipsen to seek potential marketing authorizations for Cabometyx® (cabozantinib) in advanced pancreatic and extra pancreatic neuroendocrine tumors outside of the U.S. and JapanAgreement based on CABINET Phase III trial, led by the Alliance for Clinical Trials in Oncology, which demonstrated improvements in progression-free survival for Cabometyx versus placebo 1Ipsen has engaged with regulatory authorities in the European
- GlobeNewswire
IPSEN - Buy-back programme - Art 5 of MAR - Week 25 - 2024
Aggregated presentation by day and by market Purchases of own shares from June 17th to 21th 2024 Name of the IssuerIdentity code of the IssuerDay of the transactionIdentity code of the financial instrumentTotal daily volume (in number of shares)Daily weighted average purchase price of the sharesMarket (MIC Code)IPSEN549300M6SGDPB4Z94P1117/06/2024FR00102591506 600120,3723XPARIPSEN549300M6SGDPB4Z94P1117/06/2024FR00102591502 400120,4326CEUXIPSEN549300M6SGDPB4Z94P1117/06/2024FR0010259150515120,4006T
- GlobeNewswire
IPSEN - Buy-back programme - Art 5 of MAR - Week 24 - 2024
Aggregated presentation by day and by market Purchases of own shares from June 10th to 14th 2024 Name of the IssuerIdentity code of the IssuerDay of the transactionIdentity code of the financial instrumentTotal daily volume (in number of shares)Daily weighted average purchase price of the sharesMarket (MIC Code)IPSEN549300M6SGDPB4Z94P1110/06/2024FR00102591505 000122,0351XPARIPSEN549300M6SGDPB4Z94P1111/06/2024FR00102591507 000122,0734XPARIPSEN549300M6SGDPB4Z94P1112/06/2024FR00102591501 863123,202
